Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reed Miller

Manager, Commercial/R&D

Washington, DC

Reed focuses on new technology development, including clinical trials and investment start-up companies. He has been covering medical technology since joining The Gray Sheet in 2000, and also covered cardiovascular technology for theheart.org and drug industry compliance issues for HCPro. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

Latest From Reed Miller

Cardio Catch-Up: Medtronic, Recor, Pulnovo Report Progress On Denervation To Treat Hypertension

The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.

Cardiology Approvals

Cardio Catch-Up: Medtech Innovation Takes Center Stage At TCT 2022

This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.

Cardiovascular Innovation

TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'

New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.

Clinical Trials Cardiovascular

TCT 2022: Edwards Ready To Take On Abbott In Mitral Repair Market With ‘Premium’ Device

Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.

Approvals Business Strategies

TCT 2022: Edwards' Pascal Matches Abbott's MitraClip In CLASP IID

Results of the CLASP IID trial showed Edwards’ Pascal mitral valve repair system was non-inferior for safety and effectiveness compared to Abbott’s MitraClip device.

Clinical Trials Cardiology

Insights From the Wells Fargo Health Care Conference

Medtech executives at the the Wells Fargo Healthcare Conference talked about the challenges facing them now, including hospital staffing shortages, supply chain constraints, and inflation. Here are some of the highlights from their comments

Business Strategies Commercial
See All
UsernamePublicRestriction

Register